Medicaid Expansion May Help Prevent Kidney Failure, Improve Access to Kidney-Related Care

States with broader Medicaid coverage have lower incidences of kidney failure and smaller insurance-related gaps in access to kidney disease care.
Published Online: March 21, 2014

States with broader Medicaid coverage have lower incidences of kidney failure and smaller insurance-related gaps in access to kidney disease care. Those are the findings of a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The results point to the potential benefits of Medicaid expansion on chronic disease prevention and care.

Chronic disease care is a major source of rising , and access to care for uninsured individuals with a chronic disease has eroded over the last decade. The Affordable Care Act is expanding Medicaid coverage of low-income adults, though not all states are participating in this expansion. Most previous studies of Medicaid coverage have focused on primary care or emergency room services and have not carefully examined Medicaid's effects on chronic disease care.

The care of patients approaching , or end-stage renal disease (ESRD), is a useful model to study the potential effects of Medicaid expansion on chronic disease care because ESRD care is costly and the quality of pre-ESRD care is tracked nationally.

Read the full story here: http://bit.ly/1hP851o

Source: Medical Xpress



Feature
Recommended Articles
Heterogeneity in Medicaid coverage of the anti-viral agent sofosbuvir is rampant across the United States, with varying reimbursement criteria and lack of conformation to recommendations by professional infectious disease organizations.
In an effort to better examine and understand the implementation and effects of the Affordable Care Act, researchers from the Urban Institute found that nongroup health insurance premiums in insurance marketplaces were lower than expected.
Patient-reported outcomes are beginning to influence FDA approvals and coverage decision making by payers. How oral oncolytics are affecting quality of life and patient preferences was also discussed in this fifth segment of the Oncology Stakeholders Summit, Spring 2015 series, with Bruce A. Feinberg, DO, and Brian B. Kiss, MD.
Certain exchange benefit plans have recently begun to place all specialty medications for complex diseases on the highest drug formulary cost-sharing tier, according to an analysis from Avalere Health.